ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Treatment of Post Transplant Hepatitis C (HCV) with Direct-Acting Antiviral (DAA) Agents May Improve Liver Function but Does Not Lead to an Increase in Liver Rejection

P. Sheiner, N. Mello, G. Baixauli, M. Einstein, C. Rochon, Y. Kwon, M. Bejon.

Surgery, Hartford Hospital, Hartford, CT.

Meeting: 2018 American Transplant Congress

Abstract number: 63

Keywords: Immunosuppression, Rejection

Session Information

Date: Sunday, June 3, 2018

Session Name: Concurrent Session: Liver: Immunosuppression and Rejection

Session Time: 2:30pm-4:00pm

 Presentation Time: 2:54pm-3:06pm

Location: Room 6B

Related Abstracts
  • Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
  • The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.

Previous studies have suggested that with the use of with (DAA) agents to treat post transplant (HCV), there has been an increased incidence of liver graft rejection. This increase may be due to an improvement in liver function resulting in better metabolizing of immunosuppressive drugs resulting in a decrease in blood levels or immunomodulating effects of the HCV virus. We looked to see what the effects of treating HCV post liver transplant with (DAA) agents on immunosuppressive drug levels. Patients treated with interferon were excluded from the study. Through a retrospective chart review, patients' demographics, date of transplant, date of HCV recurrence, pre and post treatment viral loads were recorded. Immunosuppressive regimens and treatment regimens were noted. Tacrolimus (TAC), cyclosporine(CYA), or sirolimus(SIR) levels were measured pretreatment, 6 weeks into treatment, and post-treatment. Post-treatment viral load as well as biopsy proven rejections was recorded as well. Following data collection, statistical analysis was done using a paired t-test. Results: 54 patients were treated with post transplant for HCV with DAA regimens. All 54 patients achieved SVR. The majority of patients were treated with TAC (41), while 9 received CYA and 4 SIR the main immunosuppression, CYA and SIR levels dropped but were not statistically significant. There was a significant decrease in TAC levels at the end of treatment (6.7 vs 4.8,p<0.02). Four patients had their dose increased. Four out of 54 patients had biopsy proven rejection (0.074) but only one was associated with a significant decrease in drug levels. The decrease of TAC level may be explained by improved hepatic function leading to enhanced drug metabolism, possibly due to the eradication of virus. While our incidence of rejection (0.07%) was low, immunosuppressive dosages and TAC levels should be monitored closely to prevent this occurrence. Thus, our study suggests that treatment of Hepatitis C may increase metabolism of TAC but does not lead to an increase in liver rejection.

CITATION INFORMATION: Sheiner P., Mello N., Baixauli G., Einstein M., Rochon C., Kwon Y., Bejon M. Treatment of Post Transplant Hepatitis C (HCV) with Direct-Acting Antiviral (DAA) Agents May Improve Liver Function but Does Not Lead to an Increase in Liver Rejection Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sheiner P, Mello N, Baixauli G, Einstein M, Rochon C, Kwon Y, Bejon M. Treatment of Post Transplant Hepatitis C (HCV) with Direct-Acting Antiviral (DAA) Agents May Improve Liver Function but Does Not Lead to an Increase in Liver Rejection [abstract]. https://atcmeetingabstracts.com/abstract/treatment-of-post-transplant-hepatitis-c-hcv-with-direct-acting-antiviral-daa-agents-may-improve-liver-function-but-does-not-lead-to-an-increase-in-liver-rejection/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.